Nuvation Bio NYSE: NUVB reported second-quarter total revenue of $31.7 million, including $23.2 mill

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and rais

Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.15 per share in line with the Zacks Co

Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst conse

Presentations Overview:WCLCTitle: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Smal

Analyses of long-term TRUST-I and TRUST-II data will examine consistency of efficacy across key pati

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings

The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirica

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and ra

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and main

NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on

Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest t

Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its

U.S. stocks saw mixed results, with Nasdaq up 150 points. AMC shares rose after beating earnings exp

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progressi

NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global onc

According to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a

FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company f

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a

NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on

Clinical-stage biotech Nuvation Bio, focused on oncology therapeutics, reported a recent insider buy

I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-dr

Nuvation Bio is upgraded to Buy, driven by Ibtrozi's growing adoption in ROS1+ NSCLC and improved mo

MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue o

Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet

  During Tuesday's session, 275 companies made new 52-week lows.

  Friday's session saw 104 companies set new 52-week lows.

  On Friday, 497 companies set new 52-week lows.

  During Friday's trading, 293 companies set new 52-week lows.

  On Friday, 64 companies achieved new lows for the year.

  On Thursday, 1076 companies hit new 52-week lows.

  On Monday, 429 stocks made new 52-week lows.

  On Monday, 92 companies set new 52-week lows.

  During Friday's session, 61 companies made new 52-week lows.

  On Thursday, 588 stocks hit new 52-week lows.